Final results of the international, expanded-access program of everolimus in patients with advanced renal cell carcinoma who progress after prior vascular endothelial growth factor receptor–tyrosine kinase inhibitor (VEGFr-TKI) therapy.
V. GrĂĽnwald
Consultant or Advisory Role - GlaxoSmithKline; Novartis; Pfizer; Roche
Honoraria - GlaxoSmithKline; Novartis; Pfizer; Roche
Research Funding - Pfizer
Other Remuneration - GlaxoSmithKline; Novartis; Pfizer
P. I. Karakiewicz
Honoraria - Bayer; Novartis; Pfizer; Roche
S. E. Bavbek
Consultant or Advisory Role - Bayer; GlaxoSmithKline; Novartis; Pfizer; Sanofi
K. Miller
Consultant or Advisory Role - Novartis
Honoraria - Novartis
J. H. Machiels
No relevant relationships to disclose
S. Lee
Consultant or Advisory Role - Novartis
Expert Testimony - Novartis
J. M. G. Larkin
Consultant or Advisory Role - AVEO; Bayer; GlaxoSmithKline; Novartis
Research Funding - Bayer; Novartis; Pfizer
P. Bono
Expert Testimony - Novartis (U)
S. Y. Rha
Consultant or Advisory Role - Novartis
D. E. Castellano
Consultant or Advisory Role - GlaxoSmithKline; Novartis; Pfizer; Roche
Honoraria - GlaxoSmithKline; Novartis; Pfizer; Roche
Research Funding - Pfizer
Other Remuneration - GlaxoSmithKline; Novartis; Pfizer
C. U. Blank
Consultant or Advisory Role - Novartis
Other Remuneration - Novartis
J. J. Knox
Research Funding - Bayer; Novartis; Pfizer
R. Hawkins
Honoraria - Novartis
R. R. Yuan
Stock Ownership - Novartis
M. Rosamilia
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
J. L. Booth
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
I. Bodrogi
No relevant relationships to disclose